Orhan Ilkay Erdogan, Senol Deniz F Sezer, Traedal-Henden Steinar, Cerón-Carrasco José P, den Haan Helena, Peña-García Jorge, Pérez-Sánchez Horacio, Emerce Esra, Skalicka-Wozniak Krystyna
Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, 06330, Ankara, Turkey.
IT-Department, UiT - the, Arctic University of Norway, 9037, Tromsø, Norway.
Chem Biodivers. 2019 May;16(5):e1900017. doi: 10.1002/cbdv.201900017. Epub 2019 Apr 10.
Cholinergic therapy based on cholinesterase (ChE) inhibitory drugs is the mainstay for the treatment of Alzheimer's disease. Therefore, an extensive research has been continuing for the discovery of drug candidates as inhibitors of acetyl- and butyrylcholinesterase. In this study, two natural molecules, e. g. hyperforin and hyuganin C were tested in vitro for their AChE and BChE inhibitory activity. Both of the compounds were ineffective against AChE, whereas hyperforin (IC =141.60±3.39 μm) and hyuganin C (IC =38.86±1.69 μm) were found to be the highly active inhibitors of BChE as compared to galantamine (IC =46.58±0.91 μm) which was used as the reference. Then, these molecules were further proceeded to molecular docking experiments in order to establish their interactions at the active site of BChE. The molecular docking results indicated that both of them are able to block the access to key residues in the catalytic triad of the enzyme, while they complement some of the hydrophobic residues of the cavity, what is consistent with our in vitro data. While both compounds were predicted as mutagenic, only hyuganin C showed hepatotoxicity in in silico analysis. According to whole outcomes that we obtained, particularly hyuganin C besides hyperforin are the promising BChE inhibitors, which can be the promising compounds for AD therapy.
基于胆碱酯酶(ChE)抑制药物的胆碱能疗法是治疗阿尔茨海默病的主要方法。因此,为发现作为乙酰胆碱酯酶和丁酰胆碱酯酶抑制剂的候选药物,广泛的研究一直在持续进行。在本研究中,对两种天然分子,即贯叶连翘素和厚朴酚C进行了体外乙酰胆碱酯酶(AChE)和丁酰胆碱酯酶(BChE)抑制活性测试。这两种化合物对AChE均无作用,而与用作对照的加兰他敏(IC =46.58±0.91 μm)相比,贯叶连翘素(IC =141.60±3.39 μm)和厚朴酚C(IC =38.86±1.69 μm)被发现是BChE的高活性抑制剂。然后,对这些分子进一步进行分子对接实验,以确定它们在BChE活性位点的相互作用。分子对接结果表明,它们都能够阻止酶催化三联体中关键残基的接近,同时它们补充了腔中的一些疏水残基,这与我们的体外数据一致。虽然两种化合物都被预测具有致突变性,但在计算机模拟分析中只有厚朴酚C表现出肝毒性。根据我们获得的整体结果,特别是厚朴酚C以及贯叶连翘素是有前景的BChE抑制剂,它们可能是治疗AD的有前景的化合物。